CLINICAL_TRIALS
trial_result
· 2020-08-20
Clinical Trial Update: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) [Phase 1]
Summary
Phase 1 dose-escalation trial of BI836826 in relapsed chronic lymphocytic leukemia (CLL) completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Status: COMPLETED | Results posted: 2020-08-20